WO2009036924A1 - Procédé pour réduire les rides - Google Patents
Procédé pour réduire les rides Download PDFInfo
- Publication number
- WO2009036924A1 WO2009036924A1 PCT/EP2008/007482 EP2008007482W WO2009036924A1 WO 2009036924 A1 WO2009036924 A1 WO 2009036924A1 EP 2008007482 W EP2008007482 W EP 2008007482W WO 2009036924 A1 WO2009036924 A1 WO 2009036924A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- product applicator
- filler
- product
- spray head
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 29
- 230000037303 wrinkles Effects 0.000 title claims description 9
- 239000002537 cosmetic Substances 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 17
- 239000007921 spray Substances 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 239000000945 filler Substances 0.000 claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 239000013543 active substance Substances 0.000 claims description 6
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 230000005693 optoelectronics Effects 0.000 claims description 4
- 230000001960 triggered effect Effects 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 229960003624 creatine Drugs 0.000 claims description 3
- 239000006046 creatine Substances 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000000155 melt Substances 0.000 claims description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 2
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims 2
- 239000003708 ampul Substances 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- 206010040954 Skin wrinkling Diseases 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000000284 extract Substances 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 235000017471 coenzyme Q10 Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 3
- -1 NaCl Chemical class 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 2
- 235000012871 Arctostaphylos uva ursi Nutrition 0.000 description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000020688 green tea extract Nutrition 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229930013032 isoflavonoid Natural products 0.000 description 2
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 2
- 235000012891 isoflavonoids Nutrition 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000037331 wrinkle reduction Effects 0.000 description 2
- KAZSKMJFUPEHHW-UHFFFAOYSA-N (2E)-3-[5-(1,1-dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl]-1-(4-hdyroxyphenyl)-2-propen-1-one Natural products COC1=CC(O)=C(C(C)(C)C=C)C=C1C=CC(=O)C1=CC=C(O)C=C1 KAZSKMJFUPEHHW-UHFFFAOYSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- SBLKVIQSIHEQOF-OWOJBTEDSA-N (e)-octadec-9-enedioic acid Chemical compound OC(=O)CCCCCCC\C=C\CCCCCCCC(O)=O SBLKVIQSIHEQOF-OWOJBTEDSA-N 0.000 description 1
- GFBCWCDNXDKFRH-UHFFFAOYSA-N 4-(oxan-2-yloxy)phenol Chemical compound C1=CC(O)=CC=C1OC1OCCCC1 GFBCWCDNXDKFRH-UHFFFAOYSA-N 0.000 description 1
- 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 description 1
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- 244000139693 Arctostaphylos uva ursi Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- IUCVKTHEUWACFB-UHFFFAOYSA-N Licochalcone A Natural products COC1=CC=C(C(C)(C)C=C)C=C1C=CC(=O)C1=CC=C(O)C=C1 IUCVKTHEUWACFB-UHFFFAOYSA-N 0.000 description 1
- KAZSKMJFUPEHHW-DHZHZOJOSA-N Licochalcone A Chemical compound COC1=CC(O)=C(C(C)(C)C=C)C=C1\C=C\C(=O)C1=CC=C(O)C=C1 KAZSKMJFUPEHHW-DHZHZOJOSA-N 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- CBQJSKKFNMDLON-JTQLQIEISA-N N-acetyl-L-phenylalanine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 CBQJSKKFNMDLON-JTQLQIEISA-N 0.000 description 1
- CAHKINHBCWCHCF-JTQLQIEISA-N N-acetyl-L-tyrosine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CAHKINHBCWCHCF-JTQLQIEISA-N 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- CIQHWLTYGMYQQR-QMMMGPOBSA-N O(4')-sulfo-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OS(O)(=O)=O)C=C1 CIQHWLTYGMYQQR-QMMMGPOBSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000032628 PAR-2 Receptor Human genes 0.000 description 1
- 108010070503 PAR-2 Receptor Proteins 0.000 description 1
- 240000004760 Pimpinella anisum Species 0.000 description 1
- 240000004064 Poterium sanguisorba Species 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 102000002020 Protease-activated receptors Human genes 0.000 description 1
- 108050009310 Protease-activated receptors Proteins 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 244000003892 Vaccinium erythrocarpum Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- BJRNKVDFDLYUGJ-ZIQFBCGOSA-N alpha-Arbutin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-ZIQFBCGOSA-N 0.000 description 1
- 229940033280 alpha-arbutin Drugs 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229930187586 licochalcone Natural products 0.000 description 1
- FCCDDURTIIUXBY-UHFFFAOYSA-N lipoamide Chemical compound NC(=O)CCCCC1CCSS1 FCCDDURTIIUXBY-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229960001682 n-acetyltyrosine Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000000065 osmolyte Effects 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- UGFMBZYKVQSQFX-UHFFFAOYSA-N para-methoxy-n-methylamphetamine Chemical compound CNC(C)CC1=CC=C(OC)C=C1 UGFMBZYKVQSQFX-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940040064 ubiquinol Drugs 0.000 description 1
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
- A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
- A61B5/442—Evaluating skin mechanical properties, e.g. elasticity, hardness, texture, wrinkle assessment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/06—Sprayers or atomisers specially adapted for therapeutic purposes of the injector type
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/02—Inhalators with activated or ionised fluids, e.g. electrohydrodynamic [EHD] or electrostatic devices; Ozone-inhalators with radioactive tagged particles
- A61M15/025—Bubble jet droplet ejection devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0468—Liquids non-physiological
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3306—Optical measuring means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
Definitions
- the present invention relates to a method for the selective application of cosmetic or pharmaceutical formulations to the skin and to a selective product applicator for cosmetic or pharmaceutical formulations.
- US 2006/0016999 A1 discloses a device which indicates to the user the type of cosmetic sunscreen preparation required. The intensity of the
- UVA and UVB radiation of sunlight detected by corresponding sensors By means of a data processing unit, the preparation needed to protect the skin is calculated on the basis of appropriately preselected data on the individual skin properties and displayed to the user via optical or acoustic signals. However, automatic application of the corresponding preparation does not take place.
- WO 04/039255 A1 discloses methods for the noninvasive analysis of the skin structure by means of optical methods. In particular, the methods shown are used to determine the melanin density.
- WO 02/087681 a method for the administration of therapeutic agents is known, in which a device implanted to the patient generates a signal which controls the delivery of an active ingredient from an adhesive plaster applied to the skin of the patient.
- a device implanted to the patient generates a signal which controls the delivery of an active ingredient from an adhesive plaster applied to the skin of the patient.
- no substances acting on or only in the upper layers of the skin can be used, since they do not or only in very small, ineffective amounts enter the body of a patient.
- the method of skin care or skin treatment is not suitable because only relatively small areas of skin can be covered with a patch. It is therefore an object of the present invention to provide a method and a suitable device which enable a selective application of cosmetic or pharmaceutical preparations for skin care or skin treatment, in particular for the treatment of wrinkles.
- the object is achieved in a first aspect by a method in which first the coloration of the skin, the skin relief or both over the entire surface of a selected skin surface is optically detected, the areas are determined within which the data deviate from target values, and then the cosmetic or pharmaceutical preparations are released on these surfaces.
- Preferred embodiments of the method are the subject of the subclaims.
- Measurements of the skin roughness on the measurement of shadows of an obliquely illuminated skin area are known. The higher the elevations or deeper the grooves in the considered skin section, the longer shadows they cast. Also known are methods for determining skin color, in which light rays reflected at the skin surface are detected. It uses the phenomenon that a light beam incident on the skin is reflected with changed wavelength distribution depending on the color of the skin. These measurements can be performed with both white light and narrowband (colored) light.
- the light reflected on the skin surface is detected via corresponding sensors.
- the change in intensity, the change in the wavelength of the reflected light or both in comparison to the incident light are detected.
- the values obtained are compared with setpoints or setpoint ranges.
- the setpoint values can be determined in advance, for example, by appropriate measurements on wrinkle-free skin areas with a lower relief depth or uniformly pigmented skin areas.
- Another method for determining the desired values is, for example, to determine average values during the measurement itself from the measured values. which are used as setpoints or setpoint range. It is important to be able to record the structure of the skin surface either line-wise (line scanner) or areal (CCD camera).
- Preparations which contain active ingredients are preferably used according to the invention.
- the choice of active ingredients depends on the type of skin change and the desired effect. Thus, for example, to smooth the skin roughness moisturizing or wrinkle-reducing agents are suitable.
- the inventive method is preferably used for targeted wrinkle reduction. Furthermore, the method according to the invention can be used for targeted treatment of acne, inflammation, redness and irritation as well as insect bites.
- the pharmaceutical or cosmetic preparations used in the process according to the invention have active substances, individually or in combination, which are suitable for the particular application.
- Suitable active ingredients are, for example, the following active ingredients selected from the group of biochinones, in particular ubiquinone (Q10), ubiquinol, folic acid and its derivatives, in particular tetrahydrofolic acid and dihydrofolic acid, niacin and its derivatives, in particular niacinamide, creatine and creatinine, carnitine, biotin, isoflavone, cardiolipin , Lipoic acid, anti-freezing proteins, Pimpinella anis fruit extract, hop and hop malt extracts, active ingredients that promote the restructuring of connective tissue, such as natural and synthetic isoflavonoids and isoflavonoid-containing plant extracts such as soy and clover extracts , Active ingredients to support the skin functions in dry skin such as vitamin C, biotin, carnitine, propionic acid, green tea extracts, eucalyptus oil, urea and mineral salts such as NaCl, marine minerals and osmolytes eg in
- Active substances in encapsulated form can also be used in the process according to the invention, in particular alpha-, beta-, HP-beta, random-Me-beta, gamma-cyclodextrin, cellulose, gelatin, wax or liposomes being used as encapsulation materials serve.
- Hyaluronic acid, Q10, folic acid, creatine, vitamin C are preferably used to treat wrinkles.
- Wrinkles can also be laminated by application of fillers, in particular by PMMA, silica or siloxane elastomers.
- the present object is achieved by a selective product applicator which has at least one optoelectronic sensor, at least one product reservoir, a data processing unit and at least one electrically triggered device for releasing liquids.
- a selective product applicator which has at least one optoelectronic sensor, at least one product reservoir, a data processing unit and at least one electrically triggered device for releasing liquids.
- Preferred embodiments of the product applicator are the subject of the subclaims.
- the optoelectronic sensors and those associated with the product reservoirs are Liquid release devices connected to the data processing unit.
- the product applicator according to the invention in the form of a pin, which can be operated or applied with one hand. All components are chosen so that they can be arranged in a housing which can be held in one hand.
- the electrically triggered device for releasing liquids has a spray head.
- the spray head can have a micropump, wherein, for example, diaphragm pumps or piston pumps are used.
- Micro diaphragm pumps often use the piezo effect (piezo diaphragm micropumps) mentioned below.
- a preferred embodiment of the present invention is the use of overpressure containers and microvalves (corresponding to the technique used in the airbrush method).
- the spray head comprises a bubble jet spray head or a piezo spray head.
- a spray head according to the bubble jet method which is referred to below as a bubble jet spray head
- tiny drops of liquid are produced by means of a heating element.
- a vapor bubble forms explosively, which presses a drop of liquid out of a nozzle by its pressure.
- a piezo spray head the property of piezocrystals is used to deform under electrical tension to force fluid through a nozzle. The drop formation of the liquid occurs, whereby the drop volume can be controlled via the applied electrical pulse.
- the operating frequency of a piezocrystal reaches up to 23 kHz.
- the active ingredients and / or preparations by microinjections directly into the folds.
- the preparation to be released must not be too hot, so that the active ingredients are not destroyed.
- the viscosity, the maximum particle size and the agglomeration behavior of the particles of the preparation to be released must also be matched to the pumping power and the nozzle geometry of the device used in order to enable a targeted release.
- CCD Charge Coupled Device
- the measured value acquisition according to the present invention is an evaluation of the light intensity distribution.
- a special optical arrangement e.g. Angle between the optical axes of the light source and the recording unit to better determine the wrinkle expression is to pay attention to the exact location assignment between the intensity signal and the application target area.
- the light intensity can be recorded as a sum signal or spectrally differentiating via optical or electronic filters.
- the trigger signal for the application can be obtained via a threshold value of the intensity or from threshold value combinations of different spectral intensities.
- the threshold value or the threshold value combinations must be determined individually for each skin in a "training mode.”
- optical iris may be required in order to focus the training particularly selectively on specific skin characteristics.
- the present object is achieved by the use of the product applicator according to the invention for the selective application of cosmetic or pharmaceutical preparations on the skin.
- the applicator according to the invention is preferred for the application of pharmaceutical and cosmetic preparations for the treatment of acne, wrinkles and other signs of aging as well as pigmentation disorders.
- Preparations suitable according to the invention are solutions, for example aqueous and / or alcoholic solutions (concentrates), emulsions, gels, melts, serums and make-up.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne un procédé d'application sélective de formulations cosmétiques ou pharmaceutiques sur la peau ainsi qu'un dispositif d'application sélective de produit destiné à des formulations cosmétiques ou pharmaceutiques.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007043698.1 | 2007-09-13 | ||
DE200710043698 DE102007043698A1 (de) | 2007-09-13 | 2007-09-13 | Selektiver Produktapplikator |
DE102008041972A DE102008041972A1 (de) | 2007-09-13 | 2008-09-10 | Verfahren zur Faltenreduktion |
DE102008041972.9 | 2008-09-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009036924A1 true WO2009036924A1 (fr) | 2009-03-26 |
WO2009036924A8 WO2009036924A8 (fr) | 2009-07-09 |
Family
ID=40011214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/007482 WO2009036924A1 (fr) | 2007-09-13 | 2008-09-11 | Procédé pour réduire les rides |
Country Status (2)
Country | Link |
---|---|
DE (1) | DE102008041972A1 (fr) |
WO (1) | WO2009036924A1 (fr) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10933156B2 (en) | 2018-02-01 | 2021-03-02 | The Procter & Gamble Company | System and method for dispensing material |
US10945515B2 (en) | 2017-06-16 | 2021-03-16 | The Procter & Gamble Company | Personal care device with audible feedback |
US11076675B2 (en) | 2017-06-16 | 2021-08-03 | The Procter & Gamble Company | Method for camouflaging tonal imperfections |
US11077689B2 (en) | 2015-12-07 | 2021-08-03 | The Procter & Gamble Company | Systems and methods for providing a service station routine |
US11083672B2 (en) | 2018-02-01 | 2021-08-10 | The Procter & Gamble Company | Cosmetic ink composition comprising a surface tension modifier |
US11090238B2 (en) | 2017-06-16 | 2021-08-17 | The Procter & Gamble Company | Array of cosmetic compositions for camouflaging tonal imperfections |
US11116302B2 (en) | 2015-06-11 | 2021-09-14 | The Procter & Gamble Company | Apparatus and methods for modifying keratinous surfaces |
USRE49230E1 (en) | 2015-06-11 | 2022-10-04 | The Procter & Gamble Company | Cartridges for use in an apparatus for modifying keratinous surfaces |
US11590782B2 (en) | 2015-12-07 | 2023-02-28 | The Procter & Gamble Company | Systems and methods for providing a service station routine |
US11833236B2 (en) | 2018-02-01 | 2023-12-05 | The Procter And Gamble Company | Heterogenous cosmetic ink composition for inkjet printing applications |
US11857665B2 (en) | 2018-02-01 | 2024-01-02 | The Procter And Gamble Company | Stable cosmetic ink composition |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021095353A (ja) * | 2019-12-16 | 2021-06-24 | ロレアル | ヒアルロン酸の液滴を使用する美容方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030065294A1 (en) * | 2001-09-28 | 2003-04-03 | Pickup Ray L. | Cutaneous administration system |
EP1459782A2 (fr) * | 2003-03-21 | 2004-09-22 | Hewlett-Packard Development Company, L.P. | Méthode et dispositif pour délivrer de manière visée des agents médiceaux où similaires |
WO2007022095A1 (fr) * | 2005-08-12 | 2007-02-22 | Yeager Rick B | Systeme et procede d'application d'un agent modifiant la reflectance pour ameliorer l'attrait visuel de la peau humaine |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001023850A1 (fr) * | 1999-09-24 | 2001-04-05 | Mahmoud Ladjevardi | Bio tomodensitometre guide et procede de coloration d'une partie du corps |
FR2810761B1 (fr) * | 2000-06-26 | 2003-09-05 | Oreal | Procede et dispositif de traitement cosmetique,notamment de soin, de maquillage ou de coloration |
WO2002087681A2 (fr) | 2001-04-30 | 2002-11-07 | Medtronic,Inc. | Appareil medical implantable, systeme de timbre et procede d'utilisation |
GB0225060D0 (en) | 2002-10-29 | 2002-12-04 | Astron Clinica Ltd | Methods and apparatus for measuring tissue histology |
US20060016999A1 (en) | 2004-07-26 | 2006-01-26 | Angelfun Enterprises Co., Ltd. | Apparatus for displaying the necessary suntan lotion and the skin care |
WO2008098235A2 (fr) * | 2007-02-11 | 2008-08-14 | Yeager Rick B | Système et procédé pour la fourniture d'images simulées via surveillance cosmétique |
DE102007043698A1 (de) * | 2007-09-13 | 2009-03-19 | Beiersdorf Ag | Selektiver Produktapplikator |
-
2008
- 2008-09-10 DE DE102008041972A patent/DE102008041972A1/de not_active Ceased
- 2008-09-11 WO PCT/EP2008/007482 patent/WO2009036924A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030065294A1 (en) * | 2001-09-28 | 2003-04-03 | Pickup Ray L. | Cutaneous administration system |
EP1459782A2 (fr) * | 2003-03-21 | 2004-09-22 | Hewlett-Packard Development Company, L.P. | Méthode et dispositif pour délivrer de manière visée des agents médiceaux où similaires |
WO2007022095A1 (fr) * | 2005-08-12 | 2007-02-22 | Yeager Rick B | Systeme et procede d'application d'un agent modifiant la reflectance pour ameliorer l'attrait visuel de la peau humaine |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11116302B2 (en) | 2015-06-11 | 2021-09-14 | The Procter & Gamble Company | Apparatus and methods for modifying keratinous surfaces |
USRE49230E1 (en) | 2015-06-11 | 2022-10-04 | The Procter & Gamble Company | Cartridges for use in an apparatus for modifying keratinous surfaces |
US11077689B2 (en) | 2015-12-07 | 2021-08-03 | The Procter & Gamble Company | Systems and methods for providing a service station routine |
US11590782B2 (en) | 2015-12-07 | 2023-02-28 | The Procter & Gamble Company | Systems and methods for providing a service station routine |
US10945515B2 (en) | 2017-06-16 | 2021-03-16 | The Procter & Gamble Company | Personal care device with audible feedback |
US11076675B2 (en) | 2017-06-16 | 2021-08-03 | The Procter & Gamble Company | Method for camouflaging tonal imperfections |
US11090238B2 (en) | 2017-06-16 | 2021-08-17 | The Procter & Gamble Company | Array of cosmetic compositions for camouflaging tonal imperfections |
US10933156B2 (en) | 2018-02-01 | 2021-03-02 | The Procter & Gamble Company | System and method for dispensing material |
US11083672B2 (en) | 2018-02-01 | 2021-08-10 | The Procter & Gamble Company | Cosmetic ink composition comprising a surface tension modifier |
US11090239B2 (en) | 2018-02-01 | 2021-08-17 | The Procter & Gamble Company | Cosmetic ink composition comprising a surface tension modifier |
US11833236B2 (en) | 2018-02-01 | 2023-12-05 | The Procter And Gamble Company | Heterogenous cosmetic ink composition for inkjet printing applications |
US11857665B2 (en) | 2018-02-01 | 2024-01-02 | The Procter And Gamble Company | Stable cosmetic ink composition |
Also Published As
Publication number | Publication date |
---|---|
DE102008041972A1 (de) | 2010-03-11 |
WO2009036924A8 (fr) | 2009-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009036876A1 (fr) | Applicateur de produit sélectif | |
WO2009036924A1 (fr) | Procédé pour réduire les rides | |
WO2009036925A1 (fr) | Procédé pour réduire les taches de vieillesse | |
CN106456005B (zh) | 用于使角质表面改性的设备和方法 | |
JP6638040B2 (ja) | 角質表面を改質するための手持ち式処理装置用アプリケータヘッド | |
JP6374991B2 (ja) | トリートメント組成物を角質表面に付着させるためのカートリッジ | |
JP6462110B2 (ja) | 角質表面を改質するための手持ち式処置装置用アプリケータヘッド | |
DE60320535T2 (de) | Elektrostatische sprühvorrichtung | |
DE60028435T2 (de) | Verwendung mindestens eines Siliconpfropfpolymers als Straffungsmittel | |
JP6820337B2 (ja) | 角質表面を改質するための処置組成物、装置及び方法 | |
US20030212129A1 (en) | System and method for revitalizing human skin | |
JP2020523135A (ja) | 可聴フィードバックを有するパーソナルケアデバイス | |
EP3154642A2 (fr) | Composition, appareil et procédés de traitement pour la modification de surfaces kératiniques | |
DE102011053514A1 (de) | Maschine zum Auftragen von Make-up auf das Gesicht und Verfahren zum Auftragen von Make-up unter Verwendung derselben | |
CA2949118A1 (fr) | Appareil et procedes de modification de surfaces keratiniques | |
CA2949119A1 (fr) | Appareil et procedes de modification de surface keratinique | |
CA3064495A1 (fr) | Methode de maquillage colorimetrique assiste par ordinateur visant a camoufler des variations de couleur de la peau | |
CN106175030A (zh) | 改变角质表面的设备和方法 | |
DE102004020644A1 (de) | Verfahren zur Bestimmung eines UVA- und UVB-Strahlung erfassenden integralen Sonnenschutzfaktors | |
WO2005002437A1 (fr) | Dispositif et procede pour determiner un niveau autorise d'exposition de la peau d'un sujet a un rayonnement uv | |
AT11794U1 (de) | Einrichtung zur photodynamischen therapie des gewebes eines lebewesens | |
EP4182673A1 (fr) | Système et procédé de mesure | |
US20240315425A1 (en) | Personal care device with audible feedback | |
EP3870373B1 (fr) | Procédé d'application d'une substance cosmétique sur la peau d'une personne | |
DE102008009471A1 (de) | Verfahren zur Depigmentierung der Haut |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08802042 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08802042 Country of ref document: EP Kind code of ref document: A1 |